Live Breaking News & Updates on Edith Mitchell|Page 2
Stay updated with breaking news from Edith mitchell. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
You talked about sitting across the table negotiating these kinds of arrangements. As you would sit across the table talking to somebody about a valuebased arrangement, one of the issues that ken identified was what if the payoff is way down the line . Would your health plan integrated Delivery System, youve got to pay the bill for the drugs today. How do you factor in a benefit that may be ten, 20, 50 years down the line . Who is that rebate check going to go to someday when that benefit crops up . Somebody enrolled in kaiser today may be someplace else, cigna, wherever else tomorrow. How do these how do you perceive these contracts are actually going to work in the real world . Well, its you know, its a combination of who benefits. And how do you project the future risk of individuals and populations based on the result that will happen today . To put it in your analogy. So in our example, we now know, because we have all of ou ....
And coming up, more on the recent health and Human Services forum on pharmaceutical innovation and drug costs. Up next, senators from medicare and medicaid acting administrator andy slavit and purchasing strategies for the pharmaceutical industries. This includes manufacturers, employers, consumers, Health Insurance providers and government officials. Once again, if you will all take your seats well get started on the final panel of the day. Where as promised, well devote our discussion to outcomes based purchasing, what is the potential for those, what are the obstacles and how do we get to better value and better accessibility for patients as soon as possible through these and other mechanisms. Let me introduce our panelists now. You have been introduced to at least this gentleman there, dan durham, Senior Vice Pr ....
Against most cancers. There are many viruses being utilized to try to take advantage of differences in cancer cells versus normal cells , that viruses may replicate in cancer cells versus not replicating. This provides opportunities to really disrupt those cancer cells and lead to death of the , but as francis mentioned, this is not as effective as one would imagine on the basis of that particular approach and paradigm. However, those viruses that are new antigens, when combined with immune modulation may provide significant opportunities to train the immune system to recognize not only viral particles but bystander mutations that are occurring in the cancer cell, so it may really prime the immune system further. There is exciting work going on with a particular engineered virus and brain cancer, which is showing impressive result that of patients. We need to understand why some patients are responding versus not. Those are exciting opportunities. I think that estimate is going to need ....
Are fit featuring an episode each day. 7 pm eastern on cspan. At tthe cspan, a look the justice y and system. The director of the equal with Ce Initiative ssince sister helen prejean. Heres a preview. Remember being shocked dead rned a lot through men walking, and people who had been executed. It shocked me profoundly. One of the things is when you write a book, you do research. I learned about police brutality. Also, when slavery was the 13th in amendment, it was except for are in prison they are indentured servants. It has not been abolished completely in this country. Have been amazed. Say it the to racism in the supreme court. Study in georgia death sentences giving, and overwhelmingly corresponds to when the victim the Death Penalty makes news when the victim makes ck, the news barely a blip. You are lucky if you can find five lines on page 30, in the case of someone from ....
I am karen brooks. I want to thank you both for a lifetime of science. Can you speak to the state of research and treatment for brain cancer and other such forms of cancer . We have made tremendous progress across many different fronts. Among the most challenging, to diseases i spent time studying in my laboratory is the brain cancer that took senator kennedys life and also pancreas cancer. There has been a tremendous amount of basic science work that has given us the atlas of genes in those cancers, really outstanding genetic model systems that help us understand what those genes do, but we are faced with converting noninformation into therapies that truly treat those diseases. I am cautiously optimistic of early data beginning to emerge in the immunotherapy space which may give us a foothold upon which we can build quite rapidly. A good example, another disease we studied because it is a very lent disease virulent diseases melanoma. In 2009 there were very few advances that had any i ....